TMTC1 Inhibitors
Chemical inhibitors of TMTC1 can impede its normal function through various mechanisms that target the glycosylation process, which is critical for the protein's proper folding, stability, and localization. Tunicamycin, by inhibiting N-linked glycosylation, directly affects the initial steps of protein glycosylation, leading to improperly folded TMTC1 due to the absence of glycan attachment. Similarly, Swainsonine and Kifunensine disrupt glycoprotein processing by inhibiting mannosidase II and mannosidase I, respectively. Their action prevents the correct trimming of mannose residues, which is necessary for the maturation of TMTC1, thus interfering with its proper function. Brefeldin A disrupts transport between the ER and the Golgi apparatus by targeting ADP-ribosylation factor, which is involved in vesicular trafficking; this can lead to the retention of TMTC1 in the ER and the accumulation of misfolded proteins.
Inhibitors like Castanospermine and the structurally related Deoxynojirimycin and 1-Deoxynojirimycin target glucosidase enzymes, which are responsible for the trimming of glucose residues in N-linked glycosylation. Their action results in the accumulation of misfolded TMTC1 proteins within the ER, as they are unable to undergo proper folding without the sequential trimming of glucose residues. Deoxymannojirimycin, as a mannosidase inhibitor, also leads to similar outcomes by affecting the processing of mannose residues, which is essential for the correct glycosylation of TMTC1. Golgicide A, which inhibits GBF1, a GEF for the Arf family of GTPases, disrupts the processing and trafficking of TMTC1 within the Golgi, while Endoglycosidase H cleaves specific oligosaccharides from N-linked glycoproteins, which can result in the removal of glycosylations crucial for TMTC1's stability and function. Lastly, Celgosivir, an alpha-glucosidase I inhibitor, impedes the enzyme that initiates the N-linked glycosylation pathway, crucial for the proper folding and localization of TMTC1, leading to its functional impairment.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Tunicamycin inhibits N-linked glycosylation, an essential process for folding and stability of many proteins. As TMTC1 is predicted to function in the oligosaccharyltransferase complex, inhibition of glycosylation can lead to improper folding and function of TMTC1. | ||||||
Swainsonine | 72741-87-8 | sc-201362 sc-201362C sc-201362A sc-201362D sc-201362B | 1 mg 2 mg 5 mg 10 mg 25 mg | $138.00 $251.00 $631.00 $815.00 $1832.00 | 6 | |
Swainsonine inhibits mannosidase II, which is crucial for glycoprotein processing in the Golgi apparatus. This disruption can prevent the proper processing and maturation of TMTC1, as it likely undergoes post-translational modifications in the Golgi. | ||||||
Kifunensine | 109944-15-2 | sc-201364 sc-201364A sc-201364B sc-201364C | 1 mg 5 mg 10 mg 100 mg | $135.00 $540.00 $1025.00 $6248.00 | 25 | |
Kifunensine is a potent inhibitor of mannosidase I, which is involved in the early processing of N-glycans in the ER. The inhibition can impact the glycosylation status and maturation of TMTC1, leading to its dysfunctional state. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A disrupts ER-to-Golgi transport by inhibiting ADP-ribosylation factor (Arf), affecting the trafficking and localization of proteins like TMTC1. Disruption of this transport can lead to an accumulation of misfolded proteins, including TMTC1, in the ER. | ||||||
Castanospermine | 79831-76-8 | sc-201358 sc-201358A | 100 mg 500 mg | $184.00 $632.00 | 10 | |
Castanospermine is a glucosidase inhibitor that blocks the trimming of glucose residues in N-linked glycosylation. This inhibition can result in misfolded TMTC1 proteins that fail to exit the ER, preventing them from reaching their functional locations in the cell. | ||||||
Deoxynojirimycin | 19130-96-2 | sc-201369 sc-201369A | 1 mg 5 mg | $73.00 $145.00 | ||
Deoxynojirimycin inhibits glucosidase I and II, enzymes involved in the processing of N-linked glycans. This inhibition can potentially interfere with the proper folding of TMTC1, leading to a loss of its function due to retention in the ER or rapid degradation. | ||||||
Deoxymannojirimycin hydrochloride | 84444-90-6 | sc-201360 sc-201360A | 1 mg 5 mg | $93.00 $239.00 | 2 | |
Deoxymannojirimycin is a mannosidase inhibitor, affecting the trimming of mannose in glycoproteins. Such inhibition can hinder the correct processing and function of TMTC1, as it is likely to be glycosylated during its maturation. | ||||||
Golgicide A | 1005036-73-6 | sc-215103 sc-215103A | 5 mg 25 mg | $191.00 $683.00 | 11 | |
Golgicide A specifically inhibits Golgi BFA resistance factor 1 (GBF1), a GEF for the Arf family of small GTPases. Inhibition of GBF1 can disrupt the Golgi processing and trafficking of TMTC1, potentially leading to its functional inhibition. | ||||||
Celgosivir | 121104-96-9 | sc-488385 sc-488385A sc-488385B | 5 mg 25 mg 100 mg | $525.00 $902.00 $2700.00 | ||
Celgosivir is an inhibitor of alpha-glucosidase I, an enzyme involved in the N-linked glycosylation pathway. Inhibition of this enzyme can lead to improper folding and mislocalization of glycoproteins, including TMTC1, thus inhibiting its proper function. | ||||||